Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) Meeting Abstract
| Authors: | Tabernero, J.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Sang Hong, Y.; Steeghs, N.; Guren, T. K.; Arkenau, H. T.; García-Alfonso, P.; Gollerkeri, A.; Pickard, M.; Maharry, K.; Christy-Bittel, J. L.; Anderson, L.; Kopetz, S. |
| Abstract Title: | Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.021 |
| Language: | English |
| ACCESSION: | WOS:000491295500156 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.021 |
| Notes: | Meeting Abstract: LBA32 -- Appears on page v868 of the abstract book -- Source: Wos |
